“…However, in the last decade, there is growing evidence that imbalance between the proangiogenic and anti angiogenic factors plays a key role in podocyte injury ( Genbacev et al, 1997 ; Fulton et al, 1999 ; Robertson et al, 2003 ; Venkatesha et al, 2006 ; Baelde et al, 2007 ; Sison et al, 2010 ; Bertuccio et al, 2011 ; Veron et al, 2012 ). This concept is supported by the observation that bevacizumab, an anti-VEGF antibody used to treat patients with various types of cancer or diabetic proliferative retinopathy causes hypertension and proteinuria mimicking the effect of sFlt-1 ( Eremina et al, 2008 ; Muller-Deile and Schiffer, 2011 ; Hayman et al, 2014 ). Interestingly, the renal findings in patients who were treated with bevacizumab including endotheliosis, thrombotic microangiopathy, and podocytes shedding, are similar to those found in preeclamptic state ( Eremina et al, 2008 ; Muller-Deile and Schiffer, 2011 ; Hayman et al, 2014 ).…”